Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$21.78 +0.5%	$21.66	$17.24 ▼ $28.43	$13.90B	0.95	989,805 shs	1.20 million shs
INSM Insmed	$108.69 +1.3%	$93.59	$60.40 ▼ $108.89	$20.35B	0.9	2.33 million shs	2.26 million shs
LNTH Lantheus	$70.57 -0.9%	$77.65	$69.12 ▼ $118.21	$4.93B	0.14	1.02 million shs	943,059 shs
TEVA Teva Pharmaceutical Industries	$15.38 -0.5%	$16.86	$12.47 ▼ $22.80	$17.72B	0.62	11.70 million shs	14.13 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+0.51%	-6.92%	+6.56%	+1.40%	-23.01%
INSM Insmed	+1.31%	+4.56%	+10.64%	+50.33%	+49.40%
LNTH Lantheus	-0.87%	-3.24%	-11.37%	-35.10%	-32.68%
TEVA Teva Pharmaceutical Industries	-0.49%	-6.98%	-9.90%	-5.18%	-11.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.6745 of 5 stars	3.3	3.0	0.0	3.9	0.0	3.1
INSM Insmed	3.784 of 5 stars	2.5	3.0	4.3	3.2	1.7	0.6
LNTH Lantheus	4.6154 of 5 stars	3.4	3.0	4.2	3.3	2.5	1.9
TEVA Teva Pharmaceutical Industries	3.979 of 5 stars	4.6	2.0	0.0	3.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	73.55% Upside
INSM Insmed	3.00	Buy	$109.20	0.47% Upside
LNTH Lantheus	2.83	Moderate Buy	$131.20	85.91% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	60.69% Upside

Current Analyst Ratings Breakdown

Latest LNTH, INSM, TEVA, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INSM Insmed	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$119.00 ➝ $130.00
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/23/2025	LNTH Lantheus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$122.00 ➝ $109.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.48	$1.52 per share	14.29	$8.04 per share	2.71
INSM Insmed	$381.03M	54.12	N/A	N/A	$1.60 per share	67.93
LNTH Lantheus	$1.53B	3.18	$7.04 per share	10.03	$15.65 per share	4.51
TEVA Teva Pharmaceutical Industries	$16.54B	1.07	$3.35 per share	4.59	$5.96 per share	2.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	12.38	12.24	6.58	35.11%	18.08%	14.52%	8/7/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/7/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	20.05	11.18	N/A	16.55%	36.99%	20.55%	8/6/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	5.85	0.91	-0.95%	46.10%	7.18%	N/A

Latest LNTH, INSM, TEVA, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	N/A	N/A	N/A	$5.77 billion	N/A
8/7/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	$104.06 million	N/A
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.34	5.32
INSM Insmed	11.38	5.86	5.44
LNTH Lantheus	0.49	5.74	5.46
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
INSM Insmed	N/A
LNTH Lantheus	99.06%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
INSM Insmed	3.00%
LNTH Lantheus	1.50%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

LNTH, INSM, TEVA, and GMAB Headlines

Recent News About These Companies

Comparing Teva Pharmaceutical Industries (NYSE:TEVA) and Globeimmune (OTCMKTS:GBIM)

August 2 at 2:23 AM | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Purchased by King Wealth Management Group

August 1 at 6:35 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Recommendation of "Buy" by Analysts

August 1 at 3:29 AM | americanbankingnews.com

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Buy" by Analysts

August 1 at 3:25 AM | marketbeat.com

Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside

July 31 at 5:48 PM | seekingalpha.com

TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales

July 31 at 1:41 PM | zacks.com

Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

July 31 at 7:38 AM | marketbeat.com

Zurcher Kantonalbank Zurich Cantonalbank Buys 36,843 Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 31 at 5:01 AM | marketbeat.com

Teva Pharm's second-quarter profit boosted by branded drugs, US tariff questions remain

July 30 at 2:29 PM | msn.com

Teva CEO: Our supply chain puts us in a strong position

July 30 at 1:04 PM | youtube.comY

Teva Pharmaceutical Industries Limited (TEVA) Q2 2025 Earnings Call Transcript

July 30 at 12:15 PM | seekingalpha.com

Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q2 Earnings: A Look at Key Metrics

July 30 at 10:36 AM | zacks.com

Teva Pharma shares climb 3% after Q2 earnings surpass expectations

July 30 at 9:27 AM | msn.com

Teva posts Q2 revenue miss as generic products underperform

July 30 at 9:27 AM | msn.com

Teva Pharmaceutical Industries Ltd Reports Q2 2025 Earnings: GAAP EPS of $0. ...

July 30 at 7:43 AM | gurufocus.com

Teva Pharm Q2 profit beats estimates as branded drugs gain

July 30 at 7:21 AM | reuters.com

36,300 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Bought by Wellington Shields & Co. LLC

July 30 at 4:11 AM | marketbeat.com

Monaco Asset Management SAM Buys Shares of 225,000 Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 30 at 4:11 AM | marketbeat.com

XTX Topco Ltd Makes New $2.46 Million Investment in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 30 at 4:11 AM | marketbeat.com

Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong

July 29, 2025 | benzinga.com

Picton Mahoney Asset Management Reduces Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNTH, INSM, TEVA, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$21.78 +0.11 (+0.51%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.78 0.00 (0.00%)

As of 08/1/2025 05:59 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Insmed NASDAQ:INSM

$108.69 +1.41 (+1.31%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$108.80 +0.12 (+0.11%)

As of 08/1/2025 07:59 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Lantheus NASDAQ:LNTH

$70.57 -0.62 (-0.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$70.74 +0.17 (+0.23%)

As of 08/1/2025 07:51 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Teva Pharmaceutical Industries NYSE:TEVA

$15.38 -0.07 (-0.45%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$15.42 +0.03 (+0.23%)

As of 08/1/2025 07:54 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time